Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids

Medicinal Chemistry

Volumn 7, Issue 1, 2011, Pages 62-69

  Thephinlap, C ^a   Phisalaphong, C ^b   Lailerd, N ^c   Chattipakorn, N ^c   Winichagoon, P ^d   Vadolus, J ^e   Fucharoen, S ^d   Porter, J B ^f   Srichairatanakool, S ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b Thailand Government Pharmaceutical Organization   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Curcuminoids; Heart rate viability; Iron; Lipid peroxidation; Thalassemia

Indexed keywords

CURCUMIN; CURCUMINOID DERIVATIVE; DEFERIPRONE; IRON; IRON CHELATE; MALONALDEHYDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA THALASSEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART DISEASE; HEART MUSCLE; HEART RATE VARIABILITY; IRON BLOOD LEVEL; IRON OVERLOAD; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BETA-THALASSEMIA; CURCUMIN; HEART; HEART RATE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; IRON, DIETARY; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TRANSFERRIN;

EID: 78751479300     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340611794072724     Document Type: Article

References (53)

1. Porter, J. B. Concepts and goals in the management of transfusional iron overload. Am. J. Hematol., 2007, 82(12 Suppl), 1136-1139.
2. Liu, Y.; Parkes, J. G.; Templeton, D. M. Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts. J. Mol. Cell. Cardiol., 2003, 35(5), 505-514.
3. Chua, A. C.; Olynyk, J. K.; Leedman, P. J.; Trinder, D. Nontransferrin- bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis. Blood, 2004, 104(5), 1519-1525.
4. Wortelboer, H. M.; Usta, M.; van der Velde, A. E.; Boersma, M. G.; Spenkelink, B.; van Zanden, J. J.; Rietjens, I. M.; van Bladeren, P. J.; Cnubben, N. H. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem. Res. Toxicol., 2003, 16(12), 1642-1651.
5. Borgna-Pignatti, C.; Vergine, G.; Lombardo, T.; Cappellini, M. D.; Cianciulli, P.; Maggio, A.; Renda, D.; Lai, M. E.; Mandas, A.; Forni, G.; Piga, A.; Bisconte, M. G. Hepatocellular carcinoma in the thalassaemia syndromes. Br. J. Haematol., 2004, 124(1), 114-117.
6. Davis, B. A.; O'Sullivan, C.; Jarritt, P. H.; Porter, J. B. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood, 2004, 104(1), 263-269.
7. Brittenham, G. M.; Griffith, P. M.; Nienhuis, A. W.; McLaren, C. E.; Young, N. S.; Tucker, E. E.; Allen, C. J.; Farrell, D. E.; Harris, J. W. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med., 1994, 331(9), 567-573.
8. Richardson, D. R. Deferiprone: greater efficacy at depleting myocardial than hepatic iron? Lancet, 2002, 360(9332), 501-502.
9. Piga, A.; Gaglioti, C.; Fogliacco, E.; Tricta, F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica, 2003, 88(5), 489-496.
10. Piga, A.; Roggero, S.; Vinciguerra, T.; Sacchetti, L.; Gallo, V.; Longo, F. Deferiprone: New insight. Ann. N. Y. Acad. Sci., 2005, 1054, 169-174.
11. Mamtani, M.; Kulkarni, H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br. J. Haematol. 2008, 141(6), 882-890.
12. McLeod, C.; Fleeman, N.; Kirkham, J.; Bagust, A.; Boland, A.; Chu, P.; Dickson, R.; Dundar, Y.; Greenhalgh, J.; Modell, B.; Olujohungbe, A.; Telfer, P.; Walley, T. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol. Assess., 2009, 13(1), iii-iv, ix-xi, 1-121.
13. Anderson, L. J.; Westwood, M. A.; Holden, S.; Davis, B.; Prescott, E.; Wonke, B.; Porter, J. B.; Walker, J. M.; Pennell, D. J. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br. J. Haematol. 2004, 127(3), 348-355.
14. La Rovere, M. T.; Pinna, G. D.; Hohnloser, S. H.; Marcus, F. I.; Mortara, A.; Nohara, R.; Bigger, J. T., Jr.; Camm, A. J.; Schwartz, P. J. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation, 2001, 103(16), 2072-2077.
15. Pandey, N.; Strider, J.; Nolan, W. C.; Yan, S. X.; Galvin, J. E. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol., 2008, 115(4), 479-489.
16. Franzoni, F.; Galetta, F.; Di Muro, C.; Buti, G.; Pentimone, F.; Santoro, G. Heart rate variability and ventricular late potentials in beta-thalassemia major. Haematologica, 2004, 89(2), 233-234.
17. Incharoen, T.; Thephinlap, C.; Srichairatanakool, S.; Chattipakorn, S.; Winichagoon, P.; Fucharoen, S.; Vadolas, J.; Chattipakorn, N., Heart rate variability in beta-thalassemic mice. Int. J. Cardiol., 2007, 121(2), 203-204.
18. Satoskar, R. R.; Shah, S. J.; Shenoy, S. G., Evaluation of antiinflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int. J. Clin. Pharmacol. Ther. Toxicol., 1986, 24(12), 651-654.
19. Nones, K.; Dommels, Y. E.; Martell, S.; Butts, C.; McNabb, W. C.; Park, Z. A.; Zhu, S.; Hedderley, D.; Barnett, M. P.; Roy, N. C. The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient ( mdr1a- / - ) mice, a model of inflammatory bowel diseases. Br. J. Nutr., 2009, 101(2), 169-181.
20. Fiorillo, C.; Becatti, M.; Pensalfini, A.; Cecchi, C.; Lanzilao, L.; Donzelli, G.; Nassi, N.; Giannini, L.; Borchi, E.; Nassi, P. Curcumin protects cardiac cells against ischemia-reperfusion injury: effects on oxidative stress, NF-kappaB, and JNK pathways. Free Radic. Biol. Med., 2008, 45(6), 839-846.
21. Wu, S. J.; Lin, Y. H.; Chu, C. C.; Tsai, Y. H.; Chao, J. C., Curcumin or saikosaponin a improves hepatic antioxidant capacity and protects against CCl4-induced liver injury in rats. J. Med. Food, 2008, 11(2), 224-229.
22. Sharma, R. A.; Ireson, C. R.; Verschoyle, R. D.; Hill, K. A.; Williams, M. L.; Leuratti, C.; Manson, M. M.; Marnett, L. J.; Steward, W. P.; Gescher, A. Effects of dietary curcumin on glutathione Stransferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin. Cancer Res., 2001, 7(5), 1452-1458.
23. Di Mario, F.; Cavallaro, L. G.; Nouvenne, A.; Stefani, N.; Cavestro, G. M.; Iori, V.; Maino, M.; Comparato, G.; Fanigliulo, L.; Morana, E.; Pilotto, A.; Martelli, L.; Martelli, M.; Leandro, G.; Franze, A. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? Helicobacter, 2007, 12(3), 238-243.
24. Aggarwal, B. B.; Kumar, A.; Bharti, A. C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 2003, 23(1A), 363-398.
25. Bernabe-Pineda, M.; Ramirez-Silva, M. T.; Romero-Romo, M. A.; Gonzalez-Vergara, E.; Rojas-Hernandez, A. Spectrophotometric and electrochemical determination of the formation constants of the complexes Curcumin-Fe(III)- water and Curcumin-Fe(II)-water. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2004, 60(5), 1105-1113.
26. Srichairatanakool, S.; Thephinlap, C.; Phisalaphong, C.; Porter, J. B.; Fucharoen, S. Curcumin contributes to in vitro removal of nontransferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma. Med. Chem., 2007, 3(5), 469-474.
27. Pongchaidecha, A.; Lailerd, N.; Boonprasert, W.; Chattipakorn, N. Effects of curcuminoid supplement on cardiac autonomic status in high-fat-induced obese rats. Nutrition, 2009, 25(7-8), 870-878.
28. Singh, S.; Hider, R. C.; Porter, J. B. A direct method for quantification of non-transferrin-bound iron. Anal. Biochem., 1990, 186(2), 320-323.
29. Sinelli, M. T.; Motta, M.; Cattarelli, D.; Cardone, M. L.; Chirico, G. Fetal hydrops in GM(1) gangliosidosis: a case report. Acta Paediatr., 2005, 94(12), 1847-1849.
30. De Chiara, B.; Crivellaro, W.; Sara, R.; Ruffini, L.; Parolini, M.; Fesslova, V.; Carnelli, V.; Fiorentini, C.; Parodi, O. Early detection of cardiac dysfunction in thalassemic patients by radionuclide angiography and heart rate variability analysis. Eur. J. Haematol., 2005, 74(6), 517-522.
31. Mahesh, S.; Ginzburg, Y.; Verma, A. Iron overload in myelodysplastic syndromes. Leuk. Lymphoma, 2008, 49(3), 427-438.
32. Banerjee, A.; Kunwar, A.; Mishra, B.; Priyadarsini, K. I. Concentration dependent antioxidant/pro-oxidant activity of curcumin studies from AAPH induced hemolysis of RBCs. Chem. Biol. Interact., 2008, 174(2), 134-139.
33. Andrews, N. C. Inherited iron overload disorders. Curr. Opin. Pediatr., 2000, 12(6), 596-602.
34. Hershko, C. Iron loading and its clinical implications. Am. J. Hematol., 2007, 82(12 Suppl), 1147-1148.
35. Tsuji, H.; Venditti, F. J., Jr.; Manders, E. S.; Evans, J. C.; Larson, M. G.; Feldman, C. L.; Levy, D. Determinants of heart rate variability. J. Am. Coll. Cardiol., 1996, 28(6), 1539-1546.
36. Tsuji, H.; Venditti, F. J., Jr.; Manders, E. S.; Evans, J. C.; Larson, M. G.; Feldman, C. L.; Levy, D. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation, 1994, 90(2), 878-883.
37. Jamsai, D.; Nefedov, M.; Narayanan, K.; Orford, M.; Fucharoen, S.; Williamson, R.; Ioannou, P. A. Insertion of common mutations into the human beta-globin locus using GET Recombination and an EcoRI endonuclease counterselection cassette. J. Biotechnol., 2003, 101(1), 1-9. (Pubitemid 36071445)
38. Ciavatta, D. J.; Ryan, T. M.; Farmer, S. C.; Townes, T. M. Mouse model of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells. Proc. Natl. Acad. Sci. U S A., 1995, 92(20), 9259-9263.
39. May, C.; Rivella, S.; Chadburn, A.; Sadelain, M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood, 2002, 99(6), 1902-1908.
40. Piga, A.; Longo, F.; Duca, L.; Roggero, S.; Vinciguerra, T.; Calabrese, R.; Hershko, C.; Cappellini, M. D. High nontransferrin bound iron levels and heart disease in thalassemia major. Am. J. Hematol., 2009, 84(1), 29-33.
41. Pippard, M. J.; Callender, S. T.; Warner, G. T.; Weatherall, D. J. Iron absorption and loading in beta-thalassaemia intermedia. Lancet, 1979, 2(8147), 819-821.
42. Esposito, B. P.; Breuer, W.; Sirankapracha, P.; Pootrakul, P.; Hershko, C.; Cabantchik, Z. I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood, 2003, 102(7), 2670-2677.
43. Fiorelli, G.; Fargion, S.; Piperno, A.; Battafarano, N.; Cappellini, M. D. Iron metabolism in thalassemia intermedia. Haematologica, 1990, 75(Suppl 5), 89-95.
44. Walter, P. B.; Fung, E. B.; Killilea, D. W.; Jiang, Q.; Hudes, M.; Madden, J.; Porter, J.; Evans, P.; Vichinsky, E.; Harmatz, P. Oxidative stress and inflammation in iron-overloaded patients with betathalassaemia or sickle cell disease. Br. J. Haematol., 2006, 135(2), 254-263.
45. Cabantchik, Z. I.; Breuer, W.; Zanninelli, G.; Cianciulli, P. LPIlabile plasma iron in iron overload. Best Pract. Res. Clin. Haematol., 2005, 18(2), 277-287.
46. Hahalis, G.; Alexopoulos, D.; Kremastinos, D. T.; Zoumbos, N. C. Heart failure in beta-thalassemia syndromes: a decade of progress. Am. J. Med., 2005, 118(9), 957-967.
47. Anuwatanakulchai, M.; Pootrakul, P.; Thuvasethakul, P.; Wasi, P. Non-transferrin plasma iron in beta-thalassaemia/Hb E and haemoglobin H diseases. Scand. J. Haematol., 1984, 32(2), 153-158.
48. Wang, W.; Abbruzzese, J. L.; Evans, D. B.; Larry, L.; Cleary, K. R.; Chiao, P. J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res., 1999, 5(1), 119-127.
49. Kardelen, F.; Tezcan, G.; Akcurin, G.; Ertug, H.; Yesilipek, A. Heart rate variability in patients with thalassemia major. Pediatr. Cardiol., 2008, 29(5), 935-939.
50. Intragumtornchai, T.; Minaphinant, K.; Wanichsawat, C.; Somabutr, C.; Posayachinda, M.; Watananukul, P.; Chinayon, C. Echocardiographic features in patients with beta thalassemia/ hemoglobin E: a combining effect of anemia and iron load. J. Med. Assoc. Thai., 1994, 77(2), 57-65.
51. Cheng, A. L.; Hsu, C. H.; Lin, J. K.; Hsu, M. M.; Ho, Y. F.; Shen, T. S.; Ko, J. Y.; Lin, J. T.; Lin, B. R.; Ming-Shiang, W.; Yu, H. S.; Jee, S. H.; Chen, G. S.; Chen, T. M.; Chen, C. A.; Lai, M. K.; Pu, Y. S.; Pan, M. H.; Wang, Y. J.; Tsai, C. C.; Hsieh, C. Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 2001, 21(4B), 2895-2900.
52. Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P. S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med., 1998, 64(4), 353-356.
53. Lao, C. D.; Demierre, M. F.; Sondak, V. K. Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert. Rev. Anticancer Ther., 2006, 6(11), 1559-1568.